U.S. FDA Grants Fast Track Designation for BioCryst’s

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
106
U.S. FDA Grants Fast Track Designation for BioCryst’s BCX7353

RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Company has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema (HAE).

Fast Track Designation provides opportunities for frequent interactions with the FDA during development of a product candidate and provides the opportunity for priority review if supported by clinical data at the time of the new drug application (NDA) submission.

“Fast Track Designation from the FDA serves as another indicator of the importance of BCX7353 to meet an unmet medical need for HAE patients in the U.S.,” said Jon P. Stonehouse, President & Chief Executive Officer. “We remain focused on completing the Phase 3 program and preparing for an NDA filing in the second half of 2019.”

About BCX7353

Discovered by BioCryst, BCX7353 is a novel, oral, once-daily, selective inhibitor of plasma kallikrein currently in development for the prevention and treatment of angioedema attacks in patients diagnosed with HAE. BCX7353 was generally safe and well tolerated in the Phase 2 APeX-1 clinical trial. BioCryst is currently conducting the Phase 3 APeX-2 clinical trial and the long-term safety APeX-S clinical trial, both evaluating two dosage strengths of BCX7353 administered orally once-daily as a preventive treatment to reduce the frequency of attacks in patients with HAE. BioCryst is also conducting the ZENITH-1 clinical trial. ZENITH-1 is a proof-of-concept Phase 2 clinical trial testing an oral liquid formulation of BCX7353 for the acute treatment of angioedema attacks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral ALK-2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP). RAPIVAB ® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com .

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that developing any HAE product candidate may take longer or may be more expensive than planned; that ongoing and future preclinical and clinical development of HAE second generation drug candidates (including ZENITH-1, APeX-2, APeX-S, and APeX-J) may not have positive results; that BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; that the Company may not advance human clinical trials with product candidates as expected; that the FDA, EMA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, or may not provide regulatory clearances which may result in delay of planned clinical trials, or may impose a clinical hold with respect to such product candidate, or withhold market approval for product candidates. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 162

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 74

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 76

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 15

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 54

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 95

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 65

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 47

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 6

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading

Top 5 Most Recently Viewed Articles

Sienna Senior Living Closes Successful Common Share Offering

Updated Category News Views 138

Sienna Senior Living Completes Successful Common Share Offering Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX:SIA) has successfully concluded a significant offering of common shares, raising approximately $144 million in gross proceeds. This achievement highlights the Company’s strong position within the senior living industry, supported by its...

Continue Reading
Discover the Richness of Japan's Honkaku Shochu in LA

Updated Category News Views 248

Shochu Rising 2025: A Celebration of Japan's Authentic Spirit The Japan Sake and Shochu Makers Association proudly presents Shochu Rising 2025, a two-day cultural event dedicated to Honkaku Shochu, Japan's exquisite distilled spirit. This celebration takes place in Los Angeles, bridging the gap between Japanese distillers and U.S. culinary professionals, media, and...

Continue Reading
Discover Unique Halloween Airblown Inflatables for Your Home

Updated Category News Views 206

Transform Your Home This Halloween with Stunning Inflatables Prepare to wow your guests and trick-or-treaters with an impressive array of Halloween decorations! This season, Gemmy has unveiled five unique Airblown Inflatables, each crafted to bring an eerie yet welcoming atmosphere to your yard. LightShow Airblown Inflatables This season, make a memorable impression with...

Continue Reading
Teamsters Unite Allegiant Air Pilots for Fair Contract Picket

Updated Category News Views 268

Allegiant Air Pilots Preparing for Nationwide Picket Teamsters Demand Fair Contract Covering 1,400 Workers Allegiant Air pilots, represented by Teamsters Local 2118, are set to hold a nationwide picket to voice their demand for a fair contract. This protest is scheduled for November 18, and it aims to address ongoing negotiation delays that have caused frustration among...

Continue Reading
Latest Earnings Insights from John Hancock Closed-End Funds

Updated Category News Views 171

Financial Highlights from John Hancock Closed-End Funds The John Hancock Closed-End Funds have recently announced their earnings for the last quarter, providing valuable insights for investors. This data sheds light on their financial position as of December 31, the comparison to the previous fiscal year gives a clearer picture of growth and performance. Understanding...

Continue Reading